Covaxin Crosses Half-Way Mark In Phase-3 Trials, Says Bharat Biotech

India's first and only phase III trial of a COVID-19 vaccine has crossed 13,000 subjects - the half-way mark - and proceeding successfully across multiple sites in India, Bharat Biotech, the maker of...